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Background: In vivo, the transforming growth factor-beta1 (TGF-β1)-induced epithelial to mesenchymal transition
(EMT) occurs in seconds during cancer cells intravasation and extravasation. Although it has been established that
cellular stiffness can change as a cancer cell transformed, the precise relationship between TGF-β1-induced
mesenchymal stem cell mechanics and cancer prognosis remains unclear. Accordingly, it is hard to define the
effects of EMT on cell mechanical properties (CMs), tumor recurrence and metastasis risks. This study bridges
physical and pathological disciplines to reconcile single-cell mechanical measurements of tumor cells.
Methods and results: We developed a microplate measurement system (MMS) and revealed the intrinsic
divergent tumor composition of retrieval cells by cell stiffness and adhesion force and flow cytometry analysis. After
flow cytometry sorting, we could measure the differences in CMs of the Sca-1+-CD44+ (mesenchymal-stem-cell-
type) and the other subgroups. As well as the stiffer and heterogeneous compositions among tumor tissues with
higher recurrence risk were depicted by MMS and atomic force microscopy (AFM). An in vitro experiment validated
that Lewis lung carcinoma (LLC) cells acquired higher CMs and motility after EMT, but abrogated by SB-505124
inhibition. Concomitantly, the CD31, MMP13 and TGF-β1 enriched micro-environment in the tumor was associated
with higher recurrence and distal lung metastasis risks. Furthermore, we report a comprehensive effort to correlate
CMs to tumor-prognosis indicators, in which a decreased body weight gain ratio (BWG) and increased tumor
weight (TW) were correlated with increased CMs.
Conclusions: Together, we determined that TGF-β1 was significantly associated with malignant tumor progressing.
In terms of clinical applications, local tumor excision followed by MMS analysis offers an opportunity to predict
tumor recurrence and metastasis risks.
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Lung cancers are among the most prevalent types of can-
cer in humans and are responsible for approximately
13.8% and 27.7% of annual cancer cases and related
deaths, respectively [1]. The vicious progression of cancer
is highly related to the epithelial-to-mesenchymal transi-
tion (EMT) [2]. Since 1994, transforming growth factor-
beta1 (TGF-β1) has been known to be an effective EMT
inducer and thus plays a key role in the early process of
cancer cell metastasis [3,4]. TGF-β1 can mediate a diverse* Correspondence: mlyeh@mail.ncku.edu.tw
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reproduction in any medium, provided the orrange of cellular responses, including the suppression of
cell proliferation [5], cytoskeleton rearrangement and
phosphorylation [6] as well as the disruption of cell-cell
junctions [7]. The active TGF-β1 has been shown increase
mesenchymal stem-like cells (MSCs), whereas inhibition
of TGF-β1 activity prevents the development of MSCs
with self-renewing and tumor-initiating capacities [8,9].
There are limited tools can identify the MSCs and TGF-
β1 activation, however, the increased cell stiffness is one
remarkable mechanical characteristic of TGF-β1 induced
EMT [10].
Recently, the cell mechanical properties (CMs) have
been proposed as an indicator of multiple cellular pro-
cesses, including cancer malignant transformation [11],. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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mising diagnostic methods, compressive stiffness might
possibly be used to predict the onset of leukostasis [18].
With magnetic tweezers, tensile stiffness phenotypes
could be measured and used to grade the metastatic po-
tential of tumor cells [19]. Change in cell stiffness is a
new characteristic of cancer cells that affects the way
they spread [20,21]. The importance of CMs to cancer is
appreciated, yet the contributions of CMs to tumor re-
currence and prognosis remain unclear.
Moreover, primary tumor excision is the standard
therapy for early defined tumors [22]. Unfortunately,
some patients with seemingly localized tumors eventu-
ally die of disseminated disease. Additionally, most stud-
ies report recurrence rates of 11% for T1 tumors and
25% for T2 tumors that were treated with local excision
alone [23,24]. The prognosis of metastatic pulmonary
tumors has been reported to be regulated by various fac-
tors such as the organs in which primary tumor is lo-
cated, the number of metastatic foci or excised tumors
and the tumor doubling time [25]. Only a few studies
have sporadically reported on prognostic factors in cases
of pulmonary metastasis. Hence, the ability to examine
prognostic factors from retrieved tumors with an accur-
ate diagnosis method is needed.
Accordingly, we endeavored to establish a microplate
measurement system (MMS) to investigate the CMs of
tumor-retrieved cells, especially the MSCs type, from
tumor-bearing mice. Eventually, we examined the correl-
ation between CMs and several tumor prognosis indica-
tors. This could benefit cancer diagnostic investigations
by providing predictable mechanical properties of tumor
recurrence and prognosis.
Results
Flow cytometry identification of tumor-retrieved cells
Flow cytometry was performed on cells that were retrieved
from first-time excised primary tumors in mice. We
assigned the cells into two groups according to the tumor
recurrence status, either non-recurrence (Non-Rec) or re-
currence (Rec). All tumor-retrieved cells were collected
from 10 different tumor-bearing mice, where 5 mice were
in the Non-Rec group and the other 5 mice were in the
Rec group. The tumor-retrieved cells were characterized by
their immunophenotypic profiles via flow cytometry. Based
on the gating parameters, we noted that the tumor-
retrieved cells were mainly composed of CD44+ Lewis lung
carcinoma (LLC) cells (Figure 1). Flow cytometry analysis
also revealed that the Sca-1+-CD44+ subgroup occupied
20.5% of the total cells from the Non-Rec group (Figure 1A)
and 63.2% from the Rec group (Figure 1B). Additionally,
the percentage of the Sca-1−-CD44− subgroup in the Non-
Rec group (28.9%) was higher than in the Rec group (8.3%).
The Sca-1+-CD44− subgroup was scarce (5.0 and 1.1%)while the Sca-1−-CD44+ subgroup was more enriched (45.6
and 27.3%) in both the Non-Rec and Rec groups.
Tumor retrieval CMs
To analyze the mechanical properties of single tumor-
retrieved cells, we choose isolated cells for microscopic
observations and measurements under a 40× objective.
We excluded the cells that early detached from the con-
canavalin A (con-A) coated backplate of cantilever,
where the tensile mechanical properties were not fully
measured. To obtain a calibration scale, 4.8 pixels/μm,
standard grid images were taken using the same object-
ive with a CCD camera (TCA-10, Tucsen, China).
Data from a total of 228 cells were collected from 10
different tumor-bearing mice, where 118 cells were in
the Non-Rec group and the other 110 cells were in the
Rec group. The average compressive stiffness (CS),
tensile stiffness (TS) and adhesion force (AF) were sig-
nificantly higher in the Rec group (CS: 539.1 ± 32.7 Pa,
TS: 693.4 ± 44.9 Pa and AF: 38.5 ± 2.3 nN) than in the
Non-Rec group (CS: 428.7 ± 22.9 Pa, TS: 601.8 ±
34.6 Pa and AF: 32.5 ± 1.7 nN) by 111 Pa (25%), 92 Pa
(15%) and 6 nN (19%), respectively (Figure 2A,B and C;
Table 1). Therefore, the MMS resolution (2 nN) was
sufficient to distinguish a difference in CMs between
the groups.
Noticeably, the measured CMs of the four subpopula-
tions of tumor-retrieved cells had a discrete distribution,
which was indicative of heterogenic mechanical proper-
ties. After sorting by flow cytometry, we obtained four
subgroups (Sca-1+-CD44+, Sca-1+-CD44−, Sca-1−-CD44+
and Sca-1−-CD44−) of tumor-retrieved cells from the
Non-Rec and Rec group. In the Rec group, the average
CS values for the Sca-1+-CD44+, Sca-1+-CD44− and Sca-
1−-CD44+ subgroups were 641.3 ± 21.2 Pa, 397.4 ±
12.9 Pa and 264.3 ± 4.8 Pa, respectively; in the Non-Rec
group, the corresponding values were 595.3 ± 11.8 Pa,
373.8 ± 8.2 Pa and 207.9 ± 17.3 Pa (Figure 2D,E and F;
Table 2). Based on the MMS measurements, the double
positive Sca-1+-CD44+ subgroup exhibited a higher aver-
age CS, TS and AF than the single positive subgroups in
both the Rec and the Non-Rec cell populations. How-
ever, no significant differences were found between the
Non-Rec and Rec groups for all CMs. The CM values of
the double negative Sca-1−-CD4− subgroup showed sig-
nificant variation among the cells, as indicated by large
standard deviations ranging from 36% to 54%.
To evaluate the distribution of cells with different
CMs, we performed Gaussian curve fits of all the CMs
data (Figure 2G,H and I). Noticeably, there are more
peaks on the Rec group curves than on the Non-Rec
group curves in general (number of peaks, Rec vs. Non-
Rec: 4 vs. 2 for CS and 4 vs. 3 for TS). For each CM
property, at least one subpopulation of cells was
Figure 1 Immunophenotypic profiles of tumor-retrieved cells. The tumor-retrieved cells from mice were labeled with PE-conjugated Sca-1
and FITC-conjugated CD44 antigens and analyzed by flow cytometry. From the (A) non-recurrence (Non-Rec) and (B) recurrence (Rec) group, the
cells that were positive for CD44 and Sca-1 were gated and then further analyzed. The percentages of gated Sca-1−-CD44−, Sca-1+-CD44−,
Sca-1−-CD44+ and Sca-1+-CD44+ cells in total tumor cells are presented on plot. All of the tumor-retrieved cells were sorted into four subgroups
and cultured separately for later analyses.
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We then determined if the nature of the cells, mesen-
chymal stem-like cells (MSCs), could be correlated to
the CMs, using data from the individual subgroups. The
regions that correspond to the Sca-1+-CD44+ subgroup,
which stand for MSCs, are indicated on the Gaussian
curves for the Non-Rec cells (average values of 595.3 ±
11.8 Pa, 674.0 ± 19.2 Pa and 39.6 ± 1.4 nN for CS, TS
and AF, respectively) and the Rec cells (average values of
641.3 ± 21.2 Pa, 700.3 ± 31.1 Pa and 43.8 ± 1.9 nN for
CS, TS and AF, respectively) (Figure 2D,E and F). The
average values of the CMs for the Sca-1+-CD44+ cells
are located within the gray areas on the frequency distri-
bution graphs (Figure 2G,H and I), which indicate the
presence of a single population of MSCs. The total per-
centages of cells from the Non-Rec group and from the
Rec group within the gray areas were 22% and 36%
based on CS distribution, 21% and 37% based on TS dis-
tribution and 39% and 52% based on AF distribution,respectively. Our cell mechanical analysis concluded that
the distribution of the CM values reflected the higher
percentage of Sca-1+-CD44+ cells, which were likely
MSCs, in the Rec population compared with the Non-
Rec population. We suggest that cell mechanical proper-
ties can be used to predict the presence of MSCs in
tumors.
AFM measurements of stiffness
We used atomic force microscopy (AFM) to measure
micron-level stiffness in the tumor tissues (Figure 3A
and B). The mean stiffness of the Non-Rec tumors was
758 ± 134.8 Pa, whereas the Rec tumors were signi-
ficantly stiffer with an average of 1095 ± 176.6 Pa
(Figure 3C; Table 1; p < 0.01). The force-mappings re-
vealed that greater amounts of heterogeneous and stif-
fer components existed in the Rec than Non-Rec
tumors (Figure 3D and E), although we could not iden-
tify which component contributed to tumor progression
and stiffening based on the AFM data alone.
Figure 2 CM measurements of the tumor-retrieved cells with different recurrence status before and after flow-cytometry sorting.
All cells were assessed with the microplate mechanical measurement system (MMS). The (A) compressive stiffness (CS), (B) tensile stiffness
(TS) and (C) adhesion force (AF) of the non-recurrence (Non-Rec) and recurrence (Rec) group were measured and graphed as the mean
(dotted line) ± SD (upper and lower index) in the scatter plots. *, p < 0.05; **, p < 0.01. (D, E and F) The red and blue bars represent the Rec
and Non-Rec groups, respectively. After sorting, each subgroup of cells was maintained separately for CM measurements. Based on the data,
the double positive subgroup had higher CMs than the single positive subgroups, and a greater variation was observed in the double negative
subgroup. (G, H and I) The distributions of the CM properties after Gaussian curve fit. Red dotted lines indicate the Rec group, and blue
dashed lines indicate the Non-Rec group. The gray areas contain the suspected mesenchymal stem cells (MSCs), which are Sca-1+-CD44+.
The number of peaks were counted after all CM data were fitted, and noticeably only one peak is present in each of the gray areas from the
Rec population.
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and TGF-β1 expression
Immunohistochemical observations of tumor sections
identified relatively fewer microvessels within the Non-
Rec tumors than within the Rec tumors (Figure 4A). The
crucial role of MMP-13 in angiogenesis promotion and
maintenance was supported by the localization of MMP-
13 near CD31, which is a known marker of endothelial
cells in newly formed blood vessels (Figure 4B). CD31 ex-
pression was circularly aligned with the vessels, and the
microvascular density (MVD) of the Rec tumors was sig-
nificantly higher (1.9-fold; p < 0.05) than that of the Non-
Rec tumors (Figure 4C). The level of autocrinally released
TGF-β1 was significantly different between the Non-Rec
group and the Rec group by 75% (Figure 4D).In vitro treatment with SB-505124 abrogates TGF-β1-
induced EMT and changes in E-cadherin expression,
cell motility and cell mechanics
To examine the effect of SB-505124 and TGF-β1 co-
treatment on Lewis lung carcinoma (LLC) cells, we first
noted that TGF-β1 treatment alone reduced the expres-
sion of the junctional E-cadherin protein by 94% in the
LLC cells. Interestingly, SB-505124 treatment reversed
TGF-β1-induced downregulation of E-cadherin in LLC
cells (Figure 5A).
In line with the change in E-cadherin expression, we
observed a functional increase in cell motility after TGF-
β1 treatment. A 24 hr wound-healing assay revealed that
the wound-closure rate of TGF-β1-treated cells that had
undergone EMT was 1.5 fold of the rate of the control
Table 1 The mechanical properties of tumor-retrieved
cells and in vitro cultured LLC cells under no treatment,
TGF-β1 treatment and SB-505124 + TGF-β1 co-treatment
Tumor-retrieval In vitro
Non-Rec Control
CS (Pa) 428.7 ± 22.9 (N = 118) CS (Pa) 384.9 ± 15.4 (N = 12)
TS (Pa) 601.8 ± 34.6 (N = 92) TS (Pa) 530.5 ± 9.9 (N = 14)
AF (nN) 32.58 ± 1.7 (N = 88) AF (nN) 27.45 ± 3.2 (N = 9)
AFM (Pa) 758.1 ± 134.8 (N = 54)
Rec TGF-β1
CS (Pa) 539.1 ± 32.7 (N = 98)** CS (Pa) 465.5 ± 29.2 (N = 13)**
TS (Pa) 693.4 ± 44.9 (N = 108)** TS (Pa) 593.7 ± 42.6 (N = 14)**
AF (nN) 38.56 ± 2.3 (N = 110)* AF (nN) 54.04 ± 9.1 (N = 15)***
AFM (Pa) 1095.0 ± 176.6 (N = 50)**
SB-505124 + TGF-β1
CS (Pa) 404.9 ± 15.4 (N = 18)
TS (Pa) 560.5 ± 9.9 (N = 18)
AF (nN) 33.5 ± 3.2 (N = 12)
CS, Compressive stiffness; TS, Tensile stiffness; AF, Adhesion force; AFM, Atomic
force microscopy-measured stiffness. Each value represents the mean ± standard
deviation (n = cell number for analysis). *P < 0.05; **P < 0.01; ***P < 0.001.
Table 2 The mechanical properties of tumor-retrieved




CS (Pa) 595.3 ± 11.8 (N = 32) CS (Pa) 641.3 ± 21.2 (N = 32)
TS (Pa) 674.0 ± 19.2 (N = 29) TS (Pa) 700.3 ± 31.1 (N = 17)
AF (nN) 39.6 ± 1.4 (N = 29) AF (nN) 43.8 ± 1.9 (N = 17)
Sca-1+-CD44− Sca-1+-CD44−
CS (Pa) 373.8 ± 8.2 (N = 26)*** CS (Pa) 397.4 ± 12.9 (N = 26)*
TS (Pa) 366.6 ± 12.3 (N = 31)** TS (Pa) 373.4 ± 14.6 (N = 23)***
AF (nN) 20.2 ± 0.8 (N = 21)*** AF (nN) 20.2 ± 0.5 (N = 21)***
Sca-1−-CD44+ Sca-1−-CD44+
CS (Pa) 207.9 ± 17.3 (N = 17)*** CS (Pa) 264.3 ± 4.8 (N = 18)***
TS (Pa) 149.1 ± 17.9 (N = 14)*** TS (Pa) 190.2 ± 13.2 (N = 28)***
AF (nN) 11.6 ± 0.8 (N = 14)*** AF (nN) 14.8 ± 1.2 (N = 12)***
Sca-1−-CD44− Sca-1−-CD44−
CS (Pa) 446.8 ± 165.5 (N = 50) * CS (Pa) 485.3 ± 265.5 (N = 34)
TS (Pa) 660.1 ± 283.7 (N = 37) * TS (Pa) 1066.0 ± 364.4 (N = 47)
AF (nN) 45.1 ± 24.6 (N = 29) * AF (nN) 64.5 ± 26.4 (N = 31)
CS, Compressive stiffness; TS, Tensile stiffness; AF, Adhesion force. Each value
represents the mean ± standard error (cell number for analysis). *P < 0.05;
**P < 0.01; ***P < 0.001.
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motility of EMT cells (Figure 5B).
A total of 14 control, 15 TGF-β1-treated and 18 SB-
505124 +TGF-β1-treated LLC cells were measured by
MMS. Interestingly, the post-EMT cells had a significantly
higher resistance to external compressive and tensile stresses
than the control cells (increments of 81 Pa (21%) and 63 Pa
(12%) in CS and TS, respectively; p < 0.05). Additionally, the
adhesion force increased markedly (27 nN; 100%) after
EMT. However, there were no significant differences be-
tween the control cells and the SB-505124 + TGF-β1-
co-treated cells for all CMs (Figure 5C; Table 1).
Metastatic and invasive abilities of tumor-retrieved cells
We removed the lung tissues and grossly observed their
integrity. Metastatic features were not seen in the Non-
Rec sample (Figure 6A). However, metastatic nodules
were identified in the lung biopsies from 2 of the Rec
group (Figure 6B). Noticeably, lung metastasis was ob-
served in 2 subjects from the Rec group that had died
on day 27 and 32 (Figure 6C). In vitro invasion assays
were performed on collagen matrigel-coated inserts, and
the migratory cell number was 26.6% less in the Non-
Rec group (42.2 ± 6.9 counts) than in the Rec group
(53.6 ± 8.5 counts; p < 0.05; Figure 6D,E and F).
Association between CMs and tumor prognosis indicators
We routinely recorded the tumor dimensions and esti-
mated the tumor volume (TV). The TV of both groups
progressively increased at a different rate. After LLCinjected for 14 days, the average TV of tumors from the
Rec group (1540.07 ± 814.54 mm3) were significantly
larger (2.8-fold) than those from the Non-Rec group
(559.82 ± 431.35 mm3; p < 0.05). After tumors excision,
we allowed recurrent tumors to develop and noted that
the TV increased drastically after day 21 (Figure 7A).
The tumor weight (TW) of the Rec group (1.62 ± 0.21
gw) was 2.2-fold over that of the Non-Rec group (0.49 ±
0.24 gw; p < 0.01; Figure 7B). There were no significant
differences in the body weight gain ratio (BWG) between
the groups. Furthermore, we observed that the BWG of
the Rec group fluctuated after day 12 and declined after
day 17. Noticeably, a growth plateau appeared at day 19
in the Non-Rec group (Figure 7C).
The relationships between the tumor prognosis markers
including TV, TW and BWG and the CMs measured
by MMS were shown in Figure 7D,E and F. There was
no significant correlation between TV and the CMs
(Figure 7D; Table 3). In contrast, TW correlated posi-
tively with tensile stiffness (r = 0.15; Figure 7E; Table 3),
while BWG correlated negatively with compressive stiff-
ness (r = −0.15), tensile stiffness (r = −0.02) and adhesion
force (r = −0.15) (Figure 7F; Table 3).
Discussions
Flow cytometry identification of tumor-retrieved cells
We hypothesized that if MSCs were involved in tumor
recurrence and metastasis to the lung from the primary
Figure 3 AFM force-mappings of freshly prepared frozen tumor slices. (A) Image of the excised tumor. (B) Phase-contrast image of the
central part of the tumor. The freshly prepared frozen tumor tissue slices were assessed by AFM. The compressive stiffness of (C) and the
error-signal images and force-mapping of (D) Non-Rec tumor and (E) Rec tumors are presented. Scale bar = 10 μm. **, p < 0.01.
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present in the primary tumors. The flow cytometry ana-
lysis showed that the cells that were retrieved from the
Rec tumors had a higher percentage of the Sca-1+-CD44+
subpopulation than the cells from the Non-Rec tumors
(Figure 1). Sca-1+-CD44+ cells have already been shown to
have a mesenchymal stem cell-like profile [26,27], to be
enriched for genes that are involved in cell motility, prolif-
eration and angiogenesis and to be associated with de-
creased patient survival and EMT [26,28]. Comparable
percentages of the Sca-1+-CD44+ subgroup were observed
between the Rec and Non-Rec groups (63.2 vs. 20.5%),
suggesting that this subgroup of cells played a role in
tumor recurrence.
Sca-1, which stands for stem cell antigen-1, is a glyco-
syl phostidylinositol-anchored cell surface protein that is
associated with both stem cell and progenitor cell activ-
ities as well as with tumor initiating potential [29].
CD44, a hyaluronic acid receptor, is a multifunctional
class I transmembrane glycoprotein. CD44 is also one of
the most commonly studied cell surface markers, which
is expressed by almost every type of cancer cells [30].
Thus, the high percentage of the CD44+ subgroup in the
Non-Rec and Rec populations indicated that cancer cells
constituted the major part of the tumors. Moreover, the
low percentage of the Sca-1+-CD44− subgroup in both
populations implied a minor representation by non-
cancerous progenitor cells. The cells without Sca-1 and
CD44 expression were stromal cells, such as fibroblasts
and endothelial cells. Using flow cytometry, we sortedthe tumor-retrieved cells into four subgroups and fur-
ther analyzed the specific role of the Sca-1+-CD44+
MSCs in tumor progression.Tumor retrieval CMs
As indicated by the flow cytometry analysis, the two
pools of tumor-retrieved cells from Non-Rec and Rec tu-
mors contained not only LLC cells but also fibroblasts
and endothelial cells and MSCs. Thus, our CM data had
wide variations. Despite the heterogeneity of cells, we
were able to differentiate the cells with different recur-
rence potential based on the CMs. We found that cells
with higher stiffness and adhesion force were more likely
to form recurrent tumors.
The complex composition of the tumor-retrieved cell
populations should not mask the ability of certain tumor
cells to undergo additional transformation to form re-
current tumors or metastases. In general, cancer cells
are typically soft and more pliant than their healthy
counterparts [12,17,31-34]. Paradoxically, biophysical
analyses have revealed that single cancer cells at any
period of tumor development may acquire increased
stiffness after TGF-β1-induced EMT, as was described
for adenocarcinoma [35] and sarcoma cells [36]. How-
ever, many cancer biologists believe that EMT is re-
quired for tumor cells to leave the primary tumor and
metastasize [37], which suggests that these stiffer cells
would need to gain the abilities to invade into the sur-
rounding tissues and bear higher stress [35].
Figure 4 Assessment of tumor malignancy based on CD31, MMP13 and TGF-β1 expression. (A) H&E staining of sliced tissue samples from
Non-Rec and Rec tumors. Areas containing angiogenic features are demarcated by the red lines and indicated with yellow arrows. The yellow
arrow-heads indicated the elongated fibroblast. An enlarged view of the angiogenic area is shown to the right of each sample. (B) Immunofluorescent
staining of Non-Rec and Rec tumor tissue samples for CD31 and MMP13. Colocalized staining of CD31 and MMP13 is indicated by the white arrows.
(C) The bar graph demonstrates the difference in microvascular density (MVD) between the groups. (D) The ELISA assay showed that TGF-β1 was
expressed in a recurrence-status-dependent manner, because the level of released TGF-β1 was lower in the culture medium from the Non-Rec group
than from the Rec group. Scale bar = 100 μm in the H&E images; Scale bar = 200 μm in the Immunofluorescent images. *, p < 0.05.
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founded by the mechanical heterogeneity of cell popula-
tions and, in the case of tumor cell studies, asynchronous
malignant status. Thus, we used an established method [38]
to purify subgroups of cells by flow cytometry. We com-
pared the CMs among the Sca-1+-CD44+, Sca-1+-CD44−
and Sca-1−-CD44+ subgroups and searched for correlations
with the cellular malignant potential. The CM values of the
Sca-1+-CD44+ cells, which were likely MSCs, were signifi-
cantly higher than those of the Sca-1+-CD44− and Sca-
1−-CD44+ subgroups, which contained the non-cancerous
progenitor cells and the non-progenitor cancer cells, re-
spectively (Figure 2D,E and F). As we know, MSCs play an
important role in cancer cell extravasation, which is charac-
terized by the facilitation of cancer cell adhesion and reten-
tion on vessel walls [39]. We assumed that the increases in
stiffness and adhesion force in the Sca-1+-CD44+ subgroup
were due to EMT that was induced by endogenous TGF-
β1 in the tumors. Taken together, these results suggest that
high stiffness and adherence force are characteristic of cells
expressing mesenchymal stem cell markers with high
tumorigenic potential, and that these cells are responsible
for tumor malignancy and metastasis. The combination of
flow cytometry and cell mechanical measurements mayserve as a tool for evaluating and sensing biological and
biomechanical changes in tumor cells, which could be clin-
ically relevant.
Interestingly, the CM values of the Sca-1−-CD44− sub-
group had large standard deviations. This result was
most likely due to the complex composition of this sub-
population, which contained cells such as fibroblasts and
endothelial cells, the stiffness of which has been previ-
ously calculated to be 1.4-6.8 kPa [40].
According to the flow cytometry analysis and the
MMS measurements (Figure 1 and 2G,H and I), the per-
centages of Sca-1- or CD44-expressing cells in the Non-
Rec and Rec groups correlated with the distribution of
the CM values. The Sca-1−-CD44+ subgroup, which con-
tained the non-progenitor cancer cells, was more repre-
sented in the Non-Rec group than in the Rec-group
(45.6% for Non-Rec vs. 27.3% for Rec) based on flow cy-
tometry analysis, and the CM profiles also reflected this
difference, where Non-Rec group had a higher percent-
age of cells with <500 Pa stiffness and <25 nN adhesion
force (the ‘soft’ cells) than the Rec-group. The rationale
of the tumor-retrieved CMs possessed tumor prognosis
responsiveness was the differentiation of specific MSCs
subgroup. Those cells had CM values between those of
Figure 5 In vitro treatment with SB-505124 abrogates TGF-β1-induced EMT and changes in E-cadherin expression, cell motility and cell
mechanics. (A) The SB-505124 + TGF-β1-treated LLC group consisted of cells that were treated with 10 ng/ml TGF-β1 in the presence of 10 μM
SB-505124 for 48 hr. Cell lysates were analyzed by western blot analysis with an anti-E-cadherin antibody. Equal loading of protein was verified by
the analysis of GAPDH. This experiment was repeated three times with similar results. The data showed that TGF-β1-treated LLC cells expressed
less E-cadherin than the untreated cells and the SB-505124 + TGF-β1 co-treated cells. E-cadherin was equally expressed in the latter two samples.
(B) Phase contrast images of the wound-healing assay are shown. The migration of the cell monolayer was observed by time-lapse microscopy
and photographed at 0, 8 and 24 h after wounding. Original magnification was 10×. The percentages of wound closure for the control, the
SB-505124 + TGF-β1-treated and the TGF-β1-treated cells were calculated from the mean of four wound widths at each time point. The average
closure rate was highest in TGF-β1-treated cells. (C) LLC cells were assessed with the MMS. TGF-β1-treated cells displayed significant differences
in stiffness and adherence when compared with the control and the SB-505124 + TGF-β1 co-treated cells based on CS, TS and AF measurements.
Scale bar = 100 μm. *, p < 0.05, **, p < 0.01, ***, p < 0.001.
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ally with CS at 500–800 Pa, TS at 500–800 Pa and AF at
25–60 nN (Figure 2G,H and I). Changes in the mechan-
ical properties of cancer cells may affect the way they
migrate, invade and disseminate.
AFM measurements of stiffness
In this study, MMS and AFM used different scales of
cell mechanical measurements, where MMS was per-
formed on single cells and AFM was performed on
tissues. Both methods revealed a positive correlation be-
tween tumor CMs and recurrence risk. Additionally, due
to the measurement scale difference, the compressive
stiffness that was detected by AFM was approximately
2-fold of the measurements by MMS (Table 1). It is
known that tumor-derived ECM is biochemically distinct
in its composition from normal ECM. Furthermore, it
has been shown that tumor stroma (∼400 Pa) is typically
stiffer than normal stroma (∼150 Pa), and that breast
cancer tissue in particular could be tenfold stiffer than
normal breast tissue (150 Pa for breast cancer stroma vs.1.5 kPa for normal breast tissue) [41-43]. During cancer
metastasis, the angiogenic process brings different types
of cells close to each other, and each cell type may pos-
sess a different degree of stiffness. For example, endothe-
lial cell layers are typically at ~1.2 kPa, and stromal
tissues, including fibroblasts or smooth muscle cells, are
typically at ~5 kPa [44]. Indeed, cancer cell dissemin-
ation is regulated in part by stiffness, and cancer cells
could often encounter stiffness gradients within a tumor
(durotaxis), which can guide cell migration.
One clinical similarity with the above observation is that
clinicians often diagnose tumors based on differences in
tissue rigidity, which are sensed by palpation. Tissue stiff-
ness can reflect the presence and the potential malignancy
of a tumor, yet the relevance of tissue stiffness to tumor
pathogenesis has been largely ignored. A previous study
found that even a small increase in matrix rigidity could
perturb tissue architecture and enhance tumor growth by
inducing Rho-generated cytoskeletal tension to promote
focal adhesion assemblies and increase ERK activation
[45]. Thus, tensional homeostasis might be essential to
Figure 6 Metastatic and invasive abilities of tumor-retrieved cells. (A, B) Representative H&E stainings of mouse lung biopsies. (A) Subjects
from the Non-Rec group were sacrificed at day 49, and no metastatic areas were found in the lungs. (B) Obvious tumor metastases were found
in the lungs of spontaneously deceased subjects in the Rec group, as marked by the yellow dotted lines. (C) The survival curve demonstrated that
2 subjects were lost due to poor prognosis and lung metastasis, and the remaining subjects were sacrificed at day 49. The tumors from all subjects
were excised at day 14 (primary, black dotted line). (D, E) Representative phase contrast images of the matrigel invasion assay. The Non-Rec
group (D) had fewer invading cells than the Rec group (E). (F) Quantification of the invasion assay results. The difference between the 2 groups
is statistically significant. Scale bars represent 100 μm and 20 μm in the H&E and invasion images, respectively. *, p < 0.05.
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toskeletal contractility to enhance integrin-dependent
growth and destabilize tissue architecture [46]. As such,
conditions that induce tissue fibrosis (matrix stiffening)
[47] or situations that amplify oncogene activity could
facilitate malignant transformation by increasing cell
contractility.
This study was conceived because tissue palpation in
the clinic inspired us to investigate if cell mechanics
might be indicators for cancer malignancy. In summary,
the combined MMS and AFM results depicted precisely
graded increments in the magnitude of CMs as the cells
emerged in the stiffer tumor microenvironment. These
altered cell-ECM interactions precede and can even con-
tribute to malignant transformation, such as the case in
leukemia [18], and the ECM in many solid tumors is
typically significantly stiffer than normal ECM [45].
Moreover, cells are known to become attuned to the
specific tissue in which they reside [48].
Assessment of tumor malignancy based on CD31, MMP13
and TGF-β1 expression
The increased angiogenesis in the Rec group tumors was
revealed by both H&E and immunofluorescent staining.
We also noted that CD31-expressing endothelial cellsoccupied the sites of angiogenesis (Figure 4A and B).
Tumor angiogenesis contributes to tumor cell prolifera-
tion and metastasis by supplying oxygen and nutrients
and removing cellular wastes [49,50].
Previously studies have reported that a decrease in the
stiffness of endothelial cells may account for the break-
down of the endothelial barrier function, suggesting that
biomechanical alterations are sufficient to facilitate the
transmigration and invasion of cancer cells into the sur-
rounding stroma [51]. It has indeed been shown that in-
vasive cancer cells may diminish the endothelial barrier
function by shedding the cell-cell adhesion receptors
from the cell surface in the presence of MMPs [51]. In
this study, we also observed the colocalization of CD31
and MMP13 in the tumor tissues (Figure 4B).
MMPs are a family of proteolytic enzymes that can de-
grade ECM components. They are thus functionally im-
portant to malignancy-associated tissue rearrangements.
Stromal MMP-13 expression is known to be required for
the invasion and metastases of breast cancer and melan-
oma [52,53]. Impaired tumor growth and metastasis
have also been shown in MMP-13-deficient mice, which
could be attributed to reduced angiogenesis [53]. Our
data suggest that host MMP-13 is responsible for blood
vessel formation and infiltration into tumor mass.




Cell mechanical properties CS 0.01 - 0.01 - 0.15*
TS - 0.01 0.15* - 0.02
AF - 0.09 - 0.11* - 0.15*
The bold text with star symbol is used to indicate a statistical association
but low.
Figure 7 Association between CMs and tumor prognosis indicators. (A) Tumor volume (TV) estimates were plotted against time, and the
dotted line represents the day of the tumor excision. The TVs of the recurrent tumors were calculated after day 21. (B) The tumor weight (TW) of
the Rec group was significantly higher than that of the Non-Rec group. (C) The body weight gain (BWG) data of all subjects were plotted against
time. (D, E, F) The regression analyses of CS (circle), TS (filled square) and AF (filled triangle) versus TV (D), TW (E) and BWG (F) are shown.
*, p < 0.05; **, p < 0.01.
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TGF-β1 in the culture medium of the Rec tumor re-
trieved cells than in the medium of the Non-Rec tumor
retrieved cells (Figure 4D), suggesting that TGF-β1
might play a role in promoting tumor recurrence. Previ-
ous studies have shown that TGF-β1 could stimulate
connective tissue formation, angiogenesis and other
changes that may favor invasion and metastasis in an
autocrine [52,54] and/or paracrine [55,56] manner.
Tumor cells can activate a stromal response that is fur-
ther amplified after MMP-digested stroma releases TGF-
β1 [57]. Thus, TGF-β1 production might be associated
with MMP activity during metastasis [58]. Shipitsin and
colleagues have shown that TGF-β1 and the TGF-β type
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breast tumors [28]. TGF-β1 is a potent inducer of EMT
in mammary cells, and its overexpression has been asso-
ciated with acquisition of tumor stem-like properties
[59]. It has also been suggested that TGF-β1 promotes
tumor invasion via its paracrine effect on tumor stroma
[60,61]. Initiation of metastasis may also start with the
signaling of TGF-β1.
In vitro treatment with SB-505124 abrogates TGF-β1-
induced EMT (EMT) and changes in E-cadherin expression,
cell motility, and cell mechanics
To further investigate the role of TGF-β1 in LLC cells, we
used SB-505124, which is a neutralizing antibody against
TGF-β1 receptors, to block TGF-β1 activity in vitro. We
used western blotting, wound healing assay and MMS to
identify changes in protein expression, cellular motility
and CMs, respectively. The delocalization of junctional
E-cadherin after TGF-β1-induced EMT can be blocked by
SB-505124 as previously reported [62]. Loss of cell-cell
contacts, increased cell migration and invasion, and deg-
radation of the extracellular matrix are all features of
EMT [63].
Our results showed that the cells underwent EMT and
acquired higher motility after TGF-β1 treatment, but the
effects were blocked by SB-505124 (Figure 5B). EMT,
which converts epithelial cells into motile mesenchymal
cells and promotes invasive and migratory properties,
plays a key role in metastasis [3,64]. Moreover, cells
without E-cadherin exhibit a contact-inhibited but accel-
erated motility and it is a prerequisite for EMT [65].
In this study, we also confirmed that the CMs were al-
tered after EMT. Compared with the control cells, the
compressive stiffness, tensile stiffness and adhesion force
of the post-EMT cells were increased by 21.1%, 11.9%
and 100%, respectively (Figure 5C, Table 1). Such incre-
ments in CMs might contribute to the early stage of
cancer cell metastasis [3], permitting cancer cells to
disseminate into sites such as the lymphatic and blood
vasculatures through EMT [64]. In an analysis of the co-
operative role of TGF-β1 in tumor development, a
higher concentration of autocrinally-released TGF-β1
was observed in the culture medium of the Rec cells but
not in the medium of the Non-Rec cells (Figure 4D). We
observed that TGF-β1 stimulation occurs in malignant
cancer cells during EMT and that alterations in the
CMs after EMT are critical for tumor recurrence and
metastasis.
From a molecular perspective, a stronger adhesion
force and self-contractile force may accelerate the motil-
ity of the EMT cells. Cytokine functions are context-
dependent, which can either promote or inhibit tumor
progression. At later stages of tumor progression, TGF-
β1 acts as a tumor promoter. It appears that the shiftfrom being a tumor suppressor to a tumor promoter is
due to increased resistance of tumor cells to the inhibitory
signals of TGF-β1 [66]. Indeed, inhibition of TGF-β recep-
tor has been shown to reverse EMT and induce a
mesenchymal-to-epithelial differentiation in CD44+ mam-
mary epithelial cells [28]. These results suggest that SB-
505124, as an EMT antagonist, could act as a ‘brake’ to
stop the accelerating motility of cells after TGF-β1 induc-
tion through the restoration of E-cadherin expression, fur-
thermore, to diminish the increased CMs.
Metastatic and invasive abilities of the tumor-retrieved cells
In our study, lung metastasis were not observed eventu-
ally in all animals. However, we observed metastatic
nodules in the lungs of 2 mice from Rec group that died
of cancer. Our observations were not surprising because
we anticipated that the tumors formed by the Rec cells
had a higher likelihood of recurrence and metastasis to
the lung compared with those that were formed by the
Non-Rec cells. The invasion assay also revealed that the
Rec cells were more invasive than the Non-Rec cells.
The bilateral molecular crosstalk between the cancer
cells and the stroma can be mediated through direct
cell-cell contacts or secreted molecules [52,54], and this
crosstalk can lead to increased invasiveness [67] and mo-
tility [68] of cancer cells. In this study, the correlation
between angiogenesis and the expression of MMP13 and
TGF-β1 also confirmed that the tumor microenviron-
ment was crucial to the promotion of tumor recurrence
and metastasis.
During the invasion assay in a mock 3D microenviron-
ment, the front parts of the cells invaded through the
porous membrane and then latched onto the opposite
side. Meanwhile, a strong traction force was needed to
drag the entire cell body through the membrane. In line
with our MMS results, the cells that successfully invaded
were those with increased stiffness and adhesion forces
due to elevated TGF-β1expression. Our results illus-
trated the importance of CMs in cancer cell invasion
and metastasis.
Association between CMs and tumor prognosis indicators
Numerous studies have investigated CM changes, using
methods such as micropipette aspiration [69-71], AFM
[72-74] and microplate mechanical systems [70,75,76],
which is now emerging as a diagnostic tool. However,
whole-cell mechanical changes remained poorly docu-
mented, and the correlation between CMs and tumor
prognosis was unknown.
We monitored the tumor growth daily. We observed
accelerated tumor growth (TV and TW) in the tumors
from the Rec group compared with the ones from the
Non-Rec group. However, the BWG ratios did not differ
between the groups. There was a possible correlation
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MMS. Higher cell tensile stiffness was found in the cells
that formed heavier tumors. It indicates that the more
rigid cells were likely more malignant and therefore pro-
liferated faster into a condensed tumor mass. All of the
CM values were inversely correlated with the BWG ra-
tio, which indicated that the CMs increased in poorly
developed tumors in response to the amount of nutri-
ents that were encroached by the tumors, leading to the
decline in the BWG ratio.
Conclusions
In this study, we defined the malignancy status (angio-
genesis, TGF-β1 expression, MMP13 expression, tumor
recurrence and lung metastasis) and poor-prognosis in-
dicators (decreased BWG and increased TV and TW)
that are associated with increased cell stiffness and adhe-
sion force. We concluded that early expression of en-
dogenous TGF-β1 affected the mechanical properties of
tumor cells as well as tumor growth, angiogenesis and
metastasis. Reciprocally, increased cell stiffness and ad-
hesion force can enhance the cell-environment contact
and crosstalk. We found that the Sca-1+-CD44+ cells
were likely candidates for disseminated or metastatic
cells, and this subpopulation was present at different
percentages in the populations of cells that were re-
trieved from the Non-Rec and Rec tumors. Our results
were also consistent with the predictions under the mes-
enchymal stem cell hypothesis. We have shown that
tumor recurrence parallels the development of metasta-
sis and that cells expressing mesenchymal stem cell
markers may be important for lung metastasis.
The stiffness of leukemia and ovarian cancer cells has
been recently used as a diagnostic marker and a marker
for chemotherapeutic response [18,19,31]. Our data also
indicate that CM properties could be used as potential
clinical biomarkers. MMS is an effective and feasible
tool to detect mechanical changes in cells, which can
then be used to predict tumor cell malignancy. There-
fore, MMS can provide novel evidence for clinical diag-
noses and therapeutic effect assessments at the cellular
level.
Methods
Xenograft mouse model and ex vivo tumor-retrieved cells
The murine lung cancer cell line (Lewis lung carcinoma,
LLC1, BCRC 60050), derived from C57/BL6 mice, was
purchased from the Bioresource Collection and Research
Center (BCRC, Taiwan). To validate the effects of TGF-
β1 induced EMT on CMs, in vitro cultured LLC were
treated with 10 ng/ml recombinant human TGF-β1
(PeproTech, London, United Kingdom) in 1% FBS-
DMEM for a 48 hr induction. The TGF-β1 receptor kin-
ase inhibitor, SB-505124, was purchased from Sigma(Sigma, USA). SB-505124 is a specific inhibitor of TGF-
β superfamily type I receptors ALK4 (activin receptor-
like kinase 4), ALK5, and ALK7 [9]. Cells were then
treated with TGF-β in the presence of SB-505124
(10 μM) for a total of 2 days.
To construct the xenograft tumor-bearing mice model,
LLC cells were inoculated into C57/BL6 mice according
to previously published methods [53,77,78]. Briefly, LLC
(106) in 100 μl PBS were injected intradermally into the
flanks of 6 to 8-week-old mice. At 2 weeks post-LLC in-
oculation, the tumor-bearing mice were anesthetized and
the tumors were removed. Subsequently, the mice were
maintained for tumor-recurrence and lung-metastasis ex-
aminations (in accordance with the National Cheng-Kung
University Animal Center standards; affidavit of approval
of animal use protocol, approval number: 101265). At
7 weeks post-inoculation, all mice were euthanized with
overdose anesthetic injections.
The tumor-retrieved cells were collected according
to a modified method [79,80]. Briefly, part of the minced
mouse tumor was digested in collagenase at 37°C for
3 hr and then filtered through sterile 58-nm nylon
mesh (BD Bioscience, CA, USA). Collected cells were
centrifuged at RT for 3 min at 800 rpm, and erythro-
cyte hemolysis was performed with RBC lysis buffer
(10 nmol/L potassium bicarbonate, 155 mmol/L ammo-
nium chloride, 0.1 mmol/L EDTA (pH 7.4)) for 5 min,
after which the suspension was again centrifuged for
5 min at 800 rpm. The pellet was resuspended in 10 ml of
fresh medium and added to a dish for incubation. Subse-
quently, the tumor-retrieved cells were washed and then
incubated on culture dishes that were coated with fi-
bronectin. After 2 days of incubation, the non-adherent
immune cells were eliminated. Subsequently, adherent
cells were harvested by trypsinization for analysis or
transplantation.
Flow cytometry analysis
Cells were washed twice with PBS and then harvested.
Detached cells (106 cells/100 μl) were resuspended in
PBS supplemented with 0.5% fetal bovine serum. Combi-
nations of fluorochrome-conjugated monoclonal anti-
bodies against mouse CD44 (FITC; cat. #11-0441) and
Sca-1 (PE; cat. #12-5981) (eBioscience, CA, USA) were
added to the cell suspensions as recommended by the
manufacturer, and the suspensions were incubated at
4°C in the dark for 20 min.
The phenotypes of cultured retrieval cells were ana-
lyzed by BD FACSaria (BD Biosciences, CA, USA) fitted
with BD FACSDiva software. Followed the previous
method [38], the compensation was performed using
single color controls. Samples were analyzed to com-
pare the negative selection antibodies against Sca-1-PE
or CD44-FITC. Sca-1+-CD44+ selection were then
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Sca-1. A post sort analysis was performed to determine
the purity of the retrieval cells. The labeled cells were
analyzed on a FACS Calibur flow cytometer (BD Biosci-
ences, CA, USA) according to the manufacturer’s
instructions.Experimental design of cell mechanics measurements
using MMS
Glass microscope slides were sterilized and coated with an
extracellular substrate layer via incubation in 10 μg/cm2
type I rat tail collagen (BD Bioscience, CA, USA) over-
night, followed by 2 washes in PBS. Suspended cells (2 ×
105 cells/ml) were allowed to adhere to the collagen-
coated slides for 4 hr before the experiment (Figure 8A
and B). Culture medium that contained 30 mM HEPES
was added to the dish to prevent pH changes over the
course of the experiment. The calibration scale under the
40× objective was 4.8 pixels/μm.Figure 8 Schema and photo image of the microplate mechanical mea
glass slide and a flexible cantilever at the opposite position. We manipulate
stepper motor, and then operated the cantilever to move along the x-axis
were adjusted perpendicular to the bottom of the petri dish above the miBefore the measurements, all flexible AFM cantilevers
were cleaned with sulfochromic acid to remove organic
compounds and were subsequently sterilized. The cleaned
cantilevers were functionalized in 0.5 mg/ml concanavalin
A (con-A; Sigma, California) for 30 min at room tem-
perature. The 3D position of the AFM probe was manually
adjusted to be near the glass slide surface and was
parallel-aligned by verifying the microscopy images in a
different focus plane than the focus drive (Figure 8A and B).
The MMS resolution was calculated from the deflection of
the cantilever multiplied by the calibrated spring constant.
Therefore, the estimated resolution was 2 nN.
Firstly, we applied a compression force through the
con-A coated flexible cantilever with a piezoelectric ac-
tuator, which was displaced to the cell by a prescribed
amount (typically 5 μm) at a constant speed (0.42 μm/s).
The reversed tension force followed, in which the canti-
lever was pulled with the cell away from collagen coated
glass slide; the cantilever was deflected until the cell
detached.surement system (MMS). (A) The MMS comprised a cell-seeding
d the cantilever by inputting commands through a computer to the
of the images shown on the monitor. (B) The component locations
croscope.
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Each cell was recognized as either a spheroid or hemi-
spheroid with rotational symmetry around the x-axis.
The x- and y-dimensions were defined as the cell height
and diameter, respectively. Axial strain (ε) was calculated
as the change in cell height (measured immediately) di-
vided by the initial cell height (measured prior to com-
pression). Additionally, the contact area (Ac) between
the cells and the cantilever was assumed to be circular
because of the symmetry of the cell shape and its value
was estimated from the measured cell diameter, which
changed progressively during measurement. The cali-
brated cantilever deflection was measured by synchron-
izing the images. The measured force (F) was calculated
with Hooke’s law from the deflection of the cantilever
multiplied by the calibrated spring constant of the canti-
lever. An image analysis program was encoded with
MATLAB software (Math Works), using the following
steps: mean filtering, histogram equalization, edge filter-
ing, edge detection, and force reduction, as performed in
a previous study [81], to detect the cantilever deflection
pixels and transform them into force measurements.




Stiffness (E) was estimated from the stress versus the




AFM measurements of stiffness
AFM was used to identify the individual tumor stiffness
that contribute to the origins of the stiffening tumor.
The bottom quarters of retrieved tumors were embed-
ded in OCT aqueous embedding compound within a
disposable plastic base mold and were snap-frozen by
direct immersion into liquid nitrogen as previously de-
scribed [82]. Frozen tissue blocks were then cut into
20-μm sections with disposable low-profile microtome
blades (Leica, 819) on a cryostat (Leica, CM1900-3-1).
The excised tumor samples from 4 animals (2 Rec and 2
Non-Rec) were used for the AFM force mapping ana-
lysis. All preparative steps were performed in a sterile
buffer supplemented with a protease inhibitor cocktail
(Sigma, CA, USA). Mechanical manipulations were kept
to a minimum at all times during sample preparation.
The atomic force microscope (JPK, NanoWizard II,
Germany) was set up for inverted microscopy (Zeiss Axio
Observer, Germany). A pyramid cantilever (P1L450B,
Nanosensors, USA) with a 1 nN-μm-sec-1 loading rate
while in contact mode was used to obtain 3 different 50 ×
50 μm2 force–volume maps over 10 × 10 point grids.Immunofluorescence and immunohistochemistry staining
Tumor and lung tissue immunostaining was performed
as previously described [83]. A hematoxylin and eosin
(H&E)-stained section was obtained from each tissue
block. To evaluate tumor angiogenesis and invasiveness,
tumor sections were stained with rat anti-mouse CD31
(1:100; Pharmingen, Heidelberg, Germany) and rabbit
anti-mouse MMP-13 (1:500; Santa Cruz Biotechnology,
Heidelberg, Germany) Subsequently, the sections were
washed with PBS and incubated with an Alexa568-
conjugated goat anti-rat secondary antibody (for CD31;
1:400; Dianova, Hamburg, Germany), and an Alexa488-
conjugated goat anti-rabbit secondary antibody (for
MMP13; 1:400; Molecular Probes, Göttingen, Germany)
for 2 hr at room temperature. The nuclei were counter-
stained with Hoechst dye H33342 (1:1000; Calbiochem-
Novabiochem, Schwalbach, Germany). The CD31, MMP13
and nucleus-conjugated fluorescent labels were excited
with lasers at 568, 488 and 405 nm, respectively, and fluor-
escence was detected with a scanning confocal microscope
(FV-1000, Olympus).
The MVD measurements were obtained simultaneously
within each area. The MVD was measured according to
Weidner’s method, in which all distinct vessels are
counted in a high power field [84]. Briefly, MVD herein
refers to the area in a tissue sample that is enclosed within
the vascular space relative to the total area.
ELISA for TGF-β1 in culture medium
The levels of TGF-β1 were determined using a TGF-β1
ELISA Kit (USCN, TX, USA) according to the manufac-
turer’s instructions. The lower limit for the cytokine de-
tection was 5 pg/ml. A total of 105 cells from each
group of tumor-retrieved cells were seeded into each
well of 12-well plate. Cells were cultured in media con-
taining 10% FBS for 18 hr, and then 100 μl of each
supernatant media was used for assay.
Western blot for E-cadherin expression
E-cadherins expressed by control, TGF-β1 and SB-505124 +
TGF-β1 treated LLC cells were examined by western
blot analysis. Cells were solubilized in lysis buffer. An
equal amount of each protein lysate were analyzed by
western blot analysis with mouse anti-E-cadherin and
anti-GAPDH polyclonal antibody (BD Biosciences, CA,
USA).
ibidi wound healing assay
By monolayer wound assay [85], we examined the effects
of SB-505124 on motility of LLC cells in response to
TGF-β1 induced EMT. Cells were induced EMT as be-
fore mentioned. The control, TGF-β1 and SB-505124 +
TGF-β1 treated cells, were kept in serum-free medium
for 24 hr. Three confluent cell groups were wounded
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grated BioDIagnostic). After washing, the medium was
replaced by normal culture medium. Photographs of the
wounded area were taken by phase–contrast microscope
with 10× objective at 0, 8 and 24 hr after wounding. For
evaluation of wound closure, four randomly selected
points along each wound were marked and the horizon-
tal distance of migrating cells from the initial wound
was measured with Image J (version 6.0; NIH).
Transwell invasion assay
Tumor-retrieved cells from every subject were allowed
to migrate across a membrane with 8-μm pores (BD
Biosciences, CA, USA) towards a medium that con-
tained 20 μg/mL FBS at 37°C, as previously described
[86]. Briefly, we first placed Transwell membrane inserts
into a 24-well plate. Next, 50 μl of collagen matrigel
(BD Biosciences, CA, USA), which had been diluted to
1 mg/ml, were added to the inserts. Next, we added
600 μl of DMEM that contained 20% FBS and 200 μl of
prepared cells (2 × 104) in DMEM containing 1% FBS to
the insert. After a 16-hr incubation, the cells on the mem-
brane were fixed and stained with methanol and Giemsa,
and the cells were counted under a 10 × objective.
Tumor prognosis indicators evaluation
The body weights and palpable tumor dimensions were
periodically evaluated every 2 days for 7 weeks with a
weight scale and beam caliper. To determine the tumor
volume (TV), the greatest longitudinal diameter (length)
and the greatest transverse diameter (width) were deter-
mined, and TV was calculated according to the modified
ellipsoid formula (Length ×Width2) [87]. At 2 weeks
post-LLC cell inoculation, the excised tumor-weights
(TW) were recorded. The body weight gain ratio (BWG)
was calculated from the increased weight divided by the
original weight of each mice.
Data analysis
Statistical analysis was performed with SPSS version 17.0
software. First, the normal distribution was verified with
the Shapiro-Wilk test. One-way ANOVA and Tukey’s
post hoc test were used to examine the differences be-
tween the groups. Pearson correlation coefficients were
established by examining the interrelationships between
the MMS and tumor prognosis factor data from each ex-
periment. A r between 0 and 0.25 was considered a low
association, between 0.25 and 0.5, a fair association, be-
tween 0.5 and 0.75, a moderate association, and > 0.75, a
high association [88]. The significance level was set at
p < 0.05.
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